EventsThe 2nd International Electronic Conference on Medicinal Chemistry and Pharmaceutics
Published
This submission belongs to the session S9. Formulation, Drug Delivery, and Controlled Release of the event The 2nd International Electronic Conference on Medicinal Chemistry and Pharmaceutics
Published date
28 Oct, 2026
Academic Editor
author-avatarMaria Emília Sousa
Contribution&Funding
Funding: The work was supported by the state assignment of the Institute of Evolutionary Physics and Biochemistry of the Russian Academy of Sciences (No. 075-00264-26-00).
Citation
Alena Pechalnova, Elena Shpakova, Kira Derkach, Alexander Shpakov, Selection of a water-containing composition for 5-amino-4-(3-aminophenyl)-N-(tert-butyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxamide (TP03), a luteinizing hormone receptor agonist: steroidogenic activity and bioavailability in male rats, in Proceedings of The 2nd International Electronic Conference on Medicinal Chemistry and Pharmaceutics, 1 November–30 November 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Selection of a water-containing composition for 5-amino-4-(3-aminophenyl)-N-(tert-butyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxamide (TP03), a luteinizing hormone receptor agonist: steroidogenic activity and bioavailability in male rats

Elena Shpakova 1
1. Laboratory of Molecular Endocrinology and Neurochemistry, Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, Saint Petersburg, 194223, Russia
Abstract

One of the areas of research in the search for effective stimulators of ovarian and testicular steroidogenesis is the development of low-molecular-weight allosteric agonists of the luteinizing hormone (LH) receptor, which offer several advantages over gonadotropins used in medicine. We previously developed 5-amino-4-(3-aminophenyl)-N-(tert-butyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxamide (TP03), a steroidogenesis and ovulation stimulator. However, TP03, being a highly hydrophobic compound, is insoluble in water and is used as a solution in DMSO, which limits its practical applications. The aim of the study was to find the optimal water-containing composition for TP03, study the ability of TP03 in this composition to stimulate testosterone production and evaluate its bioavailability for the testes. Among the studied compositions, #2 – Solutol-HS15/PEG400/water 3:2:5, and #3 - DMSO/PEG400/Tween80/phosphate buffer 1:6:1:12 were suitable for TP03. In Composition #2, TP03, when administered orally (1.5, 3 and 5 mg/kg) and intraperitoneally (15 mg/kg) to male rats, stimulated testosterone production, and the hormone level in both cases increased after 30 minutes, which was not observed when TP03 was administered in DMSO. In Composition #3, TP03 (i.p., 15 mg/kg) resulted in a gradual increase in testosterone levels, reaching a maximum after 3 hours. This effect was superior to that observed with the DMSO solution. In Compositions #2 and #3, TP03 content in the blood and testes 3 hours after oral and intraperitoneal administration exceeded those observed with the DMSO solution, indicating higher bioavailability of TP03. Thus, optimal solubilization conditions for TP03 have been selected, which is important for the development of TP03-based drugs.

The work was supported by the state assignment of the Institute of Evolutionary Physics and Biochemistry of the Russian Academy of Sciences (No. 075-00264-26-00).

Keywords
Thienopyrimidine derivatives
Luteinizing hormone receptor
Allosteric agonists
Solubilization compositions
Bioavailability
Steroidogenesis
Bioavailability of hydrophobic drugs
Water-containing compositions
Poster
Pechalnova ECMC-P 2026.pdf
ROUTE-DEPENDENT ASTAXANTHIN DELIVERY MODULATES GRANULOCYTE MITOCHONDRIAL STRESS RESPONSES
Preparation and Preliminary Evaluation of a Dissolving Microneedles Delivery System Based on Living Chlamydomonas reinhardtii